Skip to main content

14-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article

Researcher comment: The ORAL Shift trial

​​​​​​Stanley Cohen discusses the latest findings from the trial looking at methotrexate withdrawal in patients with rheumatoid arthritis achieving low disease activity with tofacitinib (2:11).

More on this trial


Related topics

More on this topic

Image Credits